Ariad asks court to restore patent-suit win against Lilly

A  federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent claim from Ariad Pharmaceuticals, according to Bloomberg News.

In 2006, a Boston jury found that two Lilly drugs—osteoporosis drug Evista and the sepsis medicine Xigris—relied on a technique licensed to Ariad, a biotechnology company based in Cambridge, Mass. The jury awarded Ariad $65.2 million and said that Lilly should pay royalties of 2.3 percent of sales of the two drugs.

However, that decision was appealed and last April was nullified by a three-judge panel, which issued a ruling that invalidated parts of Ariad’s patent. The panel said that Ariad failed to adequately describe the invention or explain how others could replicate its work.

"The description is clear and concise," John Whelan, an attorney for Ariad, told the federal appeals court on Monday.

Evista generated $1.08 billion in global sales last year for Indianapolis-based Lilly, according to Bloomberg News. The company doesn’t break out sales of Xigris.

Please enable JavaScript to view this content.

Editor's note: IBJ is now using a new comment system. Your Disqus account will no longer work on the IBJ site. Instead, you can leave a comment on stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Past comments are not currently showing up on stories, but they will be added in the coming weeks. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets in {{ count_down }} days.